Mark E Schmidt

Mark E Schmidt

UNVERIFIED PROFILE

Are you Mark E Schmidt?   Register this Author

Register author
Mark E Schmidt

Mark E Schmidt

Publications by authors named "Mark E Schmidt"

Are you Mark E Schmidt?   Register this Author

40Publications

792Reads

9Profile Views

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.

Neurology 2018 03 2;90(10):e877-e886. Epub 2018 Feb 2.

From Janssen Research & Development, LLC (E.L.), La Jolla, CA; Janssen Research & Development, LLC (D.W., G.N., S.E.), Titusville, NJ; Brigham and Women's Hospital (R.S.), Massachusetts General Hospital, Harvard Medical School, Boston; Brown University (S.S.), Providence, RI; UCL Institute of Neurology (N.C.F.), London, UK; Clinical Neurochemistry Lab, Department of Neuroscience and Physiology (K.B.), The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; VUMC (P.S.), Amsterdam, the Netherlands; Janssen Pharmaceuticals (M.E.S., J.S.), NV, Beerse, Belgium; Reference Center for Biological Markers of Dementia (BIODEM) (J.S.), Institute Born-Bunge, University of Antwerp, Belgium; Pfizer, Inc. (K.B.), Collegeville, PA; and Janssen Research & Development, LLC (N.K., H.R.B.), Fremont, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000005060DOI Listing
March 2018

The value of PET ligand discovery to CNS drug development.

Future Med Chem 2017 03 6;9(4):351-356. Epub 2017 Mar 6.

Discovery Sciences, Janssen Research & Development, Janssen-Cilag S. A., C/Jarama 75A, 45007 Toledo, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/fmc-2017-0018DOI Listing
March 2017

Dissociation of Down syndrome and Alzheimer's disease effects with imaging.

Alzheimers Dement (N Y) 2016 Jun;2(2):69-81

Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trci.2016.02.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477635PMC
June 2016

In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice.

Alzheimers Res Ther 2015 Dec 15;7(1):76. Epub 2015 Dec 15.

Molecular Imaging Center Antwerp, University of Antwerp, Campus Drie Eiken - UC, Universiteitsplein 1, 2610, Wilrijk, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13195-015-0158-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678474PMC
December 2015

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Neurology 2015 Aug 24;85(8):692-700. Epub 2015 Jul 24.

From Janssen Alzheimer Immunotherapy Research & Development, LLC (E.L., R.M., P.C., K.M.G., J.D., Y.L., I.C.T., S.B., E.Y., H.R.B.), South San Francisco, CA; Janssen Pharmaceutical (M.E.S.), Beerse, NV; Brigham & Women's Hospital (R.S.), Boston, MA; University of Michigan (R.K.), Ann Arbor; University of Pittsburgh (N.S.M., W.E.K., C.A.M.), PA; Butler Hospital (S.S.), Providence, RI; UCL Institute of Neurology (N.C.F.), London, UK; IXICO plc (D.L.H., A.S.L.), London, UK; Pfizer Inc. (B.T.W.), Groton, CT; Pfizer Inc. (K.B.), Collegeville, PA; Global R&D Partners, LLC (M.G.), San Diego, CA; and University of California (M.G.), San Diego.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000001877DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553028PMC
August 2015

Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?

Alzheimers Res Ther 2014 30;6(4):51. Epub 2014 Jul 30.

National Institute of Mental Health, 6001 Executive Boulevard, BG NSC RM 7209, Rockville, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/alzrt276DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255417PMC
December 2014

PET imaging shows loss of striatal PDE10A in patients with Huntington disease.

Neurology 2014 Jan 18;82(3):279-81. Epub 2013 Dec 18.

From University Hospitals Leuven (R.A., S.B., A.P., K.V.L., W.V.); KU Leuven (R.A., A.P., G.B., K.V.L., W.V.); and Janssen Pharmaceutica NV (M.E.S.), Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000037DOI Listing
January 2014

Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?

Eur Neuropsychopharmacol 2013 Sep 18;23(9):1043-50. Epub 2012 Sep 18.

Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, QJ;Belgium, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0924977X1200250
Publisher Site
http://dx.doi.org/10.1016/j.euroneuro.2012.08.017DOI Listing
September 2013

Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping.

EJNMMI Res 2013 Feb 14;3(1):10. Epub 2013 Feb 14.

Experimental Medicine, Janssen Research and Development, Division of Janssen Pharmaceutica, NV Turnhoutseweg 30, B-2340, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2191-219X-3-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599558PMC
February 2013

Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging.

Eur J Nucl Med Mol Imaging 2013 Jan 16;40(2):254-61. Epub 2012 Nov 16.

Division of Nuclear Medicine, University Hospital Leuven and KU Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-012-2270-1DOI Listing
January 2013

The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board.

Alzheimers Dement 2010 May;6(3):286-90

Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2010.03.010DOI Listing
May 2010

Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects.

Psychopharmacology (Berl) 2010 Jan 13;208(1):109-19. Epub 2009 Nov 13.

Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00213-009-1714-1DOI Listing
January 2010

Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.

IDrugs 2007 Nov;10(11):791-6

GlaxoSmithKline plc, London, UK.

View Article

Download full-text PDF

Source
November 2007

Functional imaging in drug discovery and development.

IDrugs 2005 Jun;8(6):497-501

Novartis Pharma AG, Clinical Imaging Unit, Klybeckstrasse 141, Basel CH 4057, Switzerland.

View Article

Download full-text PDF

Source
June 2005

Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.

J Clin Psychiatry 2004 Mar;65(3):373-8

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/jcp.v65n0313DOI Listing
March 2004

The course of depressive illness in general practice.

Can J Psychiatry 2004 Feb;49(2):119-23

Department of Psychiatry, Albert Chenevier Hospital, Créteil, France.

View Article

Download full-text PDF

Source
https://ww1.cpa-apc.org/Publications/Archives/CJP/2004/febru
Web Search
http://dx.doi.org/10.1177/070674370404900207DOI Listing
February 2004

Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo.

Nucl Med Biol 2003 Feb;30(2):187-90

Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0969-8051(02)00423-7DOI Listing
February 2003

Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment.

Biol Psychiatry 2003 Jan;53(1):100-5

Brain Imaging Center, McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts 02478, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-3223(02)01441-5DOI Listing
January 2003

Treatment approaches to major depressive disorder relapse. Part 1: dose increase.

Psychother Psychosom 2002 Jul-Aug;71(4):190-4

Lilly Research Laboratories, Indianapolis, Ind 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000063643DOI Listing
October 2002

Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.

Psychother Psychosom 2002 Jul-Aug;71(4):195-9

Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000063644DOI Listing
October 2002